Kelly Shanahan
@stage4kelly.bsky.social
Former ob/gyn. Current metastatic breast cancer patient/advocate. Grant reviewer. Conference goer. METAvivor board of directors. #NotDeadYet since 2013 she/her. #bcsm #oncsky #cansky Also: #Swiftie #SwiftieOver60
#GivingTuesday is almost here. Our Board Members have pledged $7,450 to inspire others to give. Join them and make your #GivingTuesday donation today. Your contribution helps fund the research that brings us closer to making MBC a chronic disease rather than a fatal one. metavivor.org/givingtuesday
Side effects like pneumonitis, fatigue, diarrhea plague cancer tx. Patient Centered Dosing Initiative (therightdose.org) blew the door off this topic and @fda.gov + @ascocancer.bsky.social are out with further guidelines that make sense w/new classes of drugs #cansky www.raps.org/news-and-art...
FDA, ASCO propose principles for proper dosing in cancer drug development
The US Food and Drug Administration (FDA) and the American Society of Clinical Oncology (ASCO) have laid out several principles for cancer drug developers to ensure more nuanced dosing. The principles are intended to help sponsors develop drugs that are better tolerated by patients who otherwise might suffer from long-term exposure and toxicity.
raps.org
Yup, it happens, a lot, in the metastatic breast cancer space
Darcy Burbage, DNP, RN, AOCN@darcyburbage.bsky.social · last yr.Cancer ghosting may be linked to cancer stigma, which can lead to increased suffering & health disparities & is one more emotional toll for pts who are likely to feel overwhelmed w/anxiety re: their diagnosis & treatment. @ekdrake.bsky.social @coffeemommy.bsky.social www.ons.org/publications...
When researchers and patient advocates work together we are #StrongerTogether #SmarterTogether
Hillary Andrews, PhD@hillstirsci.bsky.social · last yr.Our manuscript highlighting the design, goals, and experiences of the MBCRC Advocate Researcher Program (MARP), which focused on building meaningful, bidirectional partnerships between advocates and researchers was published in npj breast. www.nature.com/articles/s41...
Fantastic to see work focusing on #MaleBreastCancer l! #bcsm
Dana-Farber’s Breast Oncology Center@dfcibreastonc.bsky.social · last yr.@dfcibreastonc.bsky.social and the TBCRC are leading the #ETHANstudy, which evaluates endocrine therapies to identify the best treatment for men with ER+/HER2- breast cancer prior to surgery. #MaleBreastCancer For more information call 877-338-7425 or visit: www.dana-farber.org/clinical-tri...
Ever heard of #StageIVStampede? Its 2 days of #MBCAdvocacy, legislative training & education presented by @metavivor.bsky.social in Washington, D.C. @stage4kelly.bsky.social discusses how the MBC community unites for change. 🎧 Listen (all channels) or 🔗 buff.ly/HIA9xIT #trailblazers #BCSM #CanSky
As a person #NotDeadYet with metastatic breast cancer this is incredibly disheartening.
Nature@nature.com · last yr.The massive changes in US research brought about by the new administration of President Donald Trump are causing many scientists in the country to rethink their lives and careers https://go.nature.com/41OhAgK
non-Governmental research funding is becoming more important every day. @metavivor.bsky.social received almost double the usual number of letters of intent last week. We need our supporters to be generous this year so we can fund promising research!
I’ve had ☢️ ⚡️ before, to my 🦴. Piece of 🍰. Just finished 5 days of SBRT to my liver. “It’ll be 🍰” I thought. My liver: 😈 😆 Me: 🤢 🥱 😕 #MetastaticBreastCancer #SideEffucks #bcsm #NotDeadYet
Thrilled to be on the @metavivor.bsky.social board of directors and share this announcement of our 2024 research awards on #WorldCancerDay!! The 2025 cycle opens this week (2/5 - translational, 2/6 - early career, 2/7 - quality of life). Check out www.metavivor.org/research/gra... for details
Grant Programs - Metastatic Breast Cancer Research Grants | METAvivor
Learn about grant programs for METAvivor, a group dedicated to curing stage 4 breast cancer.
metavivor.org
METAvivor@metavivor.bsky.social · last yr.METAvivor is funding $3.75M in new grants for 12 research projects on metastatic breast cancer! This funding is a step forward in improving treatments & driving breakthroughs for MBC patients. Read more here: www.metavivor.org/blog/metaviv... #MBCResearch
Even with @metavivor.bsky.social’s new 90/10 split of donations they’ll still be putting a higher percent into research and programs than any other cancer nonprofit I could find
METAvivor@metavivor.bsky.social · 2y ago#METAvivor #MetastaticBreastCancer #Transparency #ThankYou #DonorPolicy
Since our government will no longer recognize it, let me wish everyone happy Black History Month, and remind you that Black history is American history. We are a better nation because of diversity.
I have spent so much time on my phone today, posting and answering emails, that when I just sat down to take a break with a physical book I tried to swipe up to turn the page 😂
a cartoon of a girl carrying a stack of books with the website bibliotheca.com written below her
ALT: a cartoon of a girl carrying a stack of books with the website bibliotheca.com written below her
media.tenor.com
Hey #oncsky #bcsm friends: METAvivor is here!! @metavivor.bsky.social
I ran @USAID health programs for the last 3 years. Trump’s 90 day Stop Work Order on foreign assistance does serious damage to the world and the US. Examples:🧵
It’s been a week since Trump’s pause on HHS communications and, despite some clarifications, new NIH research funding is still at a standstill. With the freeze on external communications expected to last until Feb. 1, how might this impact funding? 🧵 ⬇️
It was so fun to talk all things #FinancialToxicity with Drs @fumikochino.bsky.social and @ryannipp.bsky.social on @ascocancer.bsky.social’s podcast- just wish it could have been in person!
Fumiko Ladd Chino, MD FASCO@fumikochino.bsky.social · 2y ago🎙️Beyond excited to relaunch a @ascocancer.bsky.social podcast with 1st episode: "Debt or Dying: The JCOOP #FinancialToxicity Special Issue". My guests are Drs @ryannipp.bsky.social (my co-editor) & @stage4kelly.bsky.social (contributing author to the title piece on the lived experience of patients).
#TumorBoardTuesday We have not heard any updates from #SABCS24 yet! 📢So join us Tuesday, 01-14-25 at 8PM ET here & on Twitter as @dr-rshatsky.bsky.social & @zoezhang.bsky.social🗣️SERDS & novel Tx for HR+ #breastcancer RT and bring others into the discussion‼️
Thank you @ascocancer.bsky.social for devoting an entire issue of JCO OP to the topic of #FinancialToxicity and thank you to @fumikochino.bsky.social @ryannipp.bsky.social for inviting me to 🖊️ a piece for this, on my experience with financial toxicity as someone with privilege and savings.
Fumiko Ladd Chino, MD FASCO@fumikochino.bsky.social · 2y ago🚨 The #FinancialToxicity special issue of JCO OP is LIVE today! 🚨 We hope these papers will encourage the next gen of researchers to generate, evaluate, & disseminate patient-centered, high-quality, evidence-based medicine & policy solutions to close the affordability gap! ascopubs.org/toc/op/21/1
Let’s try this whole “word for the year” thing. Between cancer/cancer advocacy stuff and the incoming administration, I think this one will serve me well.
Are you living with metastatic breast cancer? Are you interested in liquid biopsy? Join us tomorrow for what is certain to be a lively discussion of two posters presented at SABCS24! graspcancer.org/events/sabcs...
Group 5G: Metastatic Breast Cancer; ER+; Liquid Biopsy; Biomarkers - Grasp Cancer
Poster #P3-10-10: Sequencing PIK3CA and AKT Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Retrospective Analysis Poster #P1-05-19: Circulating Tumor DNA as a Pro...
graspcancer.org
Love, love, LOVE how #advocate extraordinaire @coffeemommy.bsky.social of @advocatecollab.bsky.social reminds the moderator, the panel, and the audience that #WordsMatter - “deescalation” sounds like “you don’t matter, we’ll do less” so preferred terminology is “right-sizing”. #SABCS24
Also for ER+ (b/c I’m still ER+) is DB06, where there was efficacy even in HER2 ultra low (seriously, where is TDXd (Enhertu) NOT effective - it crosses the BBB too! #SABCS24
